Tesamorelin Research Lab Test Recommendations for Wholesale Buyers

A defensible analytical package for research-grade tesamorelin answers three separate questions, and no single assay answers more than one of them: identity (is the material actually the 44-amino-acid growth hormone-releasing hormone analog named on the label), purity (what proportion of the detectable material is the target sequence rather than synthesis by-products), and composition and contamination (how much of the vial's mass is peptide rather than water and counter-ion, and whether endotoxin, bioburden, heavy metals or residual solvents were screened at all). Require a lot-specific certificate of analysis whose lot number matches the vial in front of you, require the chromatogram rather than the headline percentage alone, and confirm which assays were run by a laboratory that does not report to the seller. Everything below concerns material sold for laboratory research use only.

Why a purity percentage is the weakest number on the page

Purity is the figure suppliers quote most often and the figure that carries the least information on its own. A percentage with no method attached does not tell you which analytical technique produced it, at what detection wavelength, whether it is expressed as relative peak area or as net peptide content, or how well the method separated the target peak from anything eluting beside it. Two lots can both be described as 99% and be materially different preparations.

Chain length is the reason this matters more for tesamorelin than for the short peptides that dominate most catalogs. Tesamorelin is a synthetic analog of human GHRH built on a 44-residue backbone, which means dozens of sequential coupling steps during synthesis. Every step is slightly imperfect, so the crude product contains deletion sequences missing a single residue, incompletely deprotected fragments, and oxidation or deamidation products. Those relatives are chemically very similar to the target, which is exactly why they can elute close to it and hide inside a broad main peak. Research on GHRH analogs concerns receptor signaling at the pituitary level and is mechanistic literature about the molecule; it says nothing about outcomes in people, and it is not a reason to relax analytical scrutiny.

The practical consequence: a long peptide needs a method that demonstrates resolution, not just a number that implies it. Ask what the method was designed to separate before you accept what it reports.

The assay set worth requiring on every lot

No supplier runs every row on every lot, and any vendor claiming otherwise without documents is asking for trust rather than offering evidence. The goal of the table is not a wish list — it is a map of coverage. Know which questions the certificate answers, which it leaves open, and which gaps you are willing to accept for your own use case.

Reading an HPLC result the way an analyst would

A usable chromatographic report names its conditions: column chemistry and dimensions, mobile phase and modifier, gradient profile, flow rate, injection concentration, detection wavelength and retention time of the main peak. Peptide bonds absorb strongly in the low ultraviolet range, so peptide purity is normally reported near 214–220 nm; a result reported only at 280 nm depends on aromatic residues and can flatter a sample by leaving non-absorbing impurities invisible. If the wavelength is missing, the number is unanchored.

Then look at the trace itself rather than the summary line. Is the baseline stable, or is the integration drawing a generous box around drift? Is the main peak symmetrical, or does it carry a shoulder that a steep gradient has folded into the same integration window? What is the size of the largest single impurity, not just the total? Reviewers who only read the total percentage miss the difference between a lot with many trace impurities and a lot with one substantial co-eluting relative — the second is the bigger problem, and it is the one a shallow gradient is designed to expose.

Retention time earns attention too. Compared against a reference standard run under the same method, retention time is weak supporting evidence of identity. Compared against nothing, it is decoration. This is the single most useful request a buyer can make of any supplier: send the chromatogram image for this lot, not the summary. A PDF that states a number and shows no trace is an assertion; a trace is data you can have someone else read.

Confirming identity, not just cleanliness

Purity describes how homogeneous a sample is. It says nothing about what the sample is. A flawlessly pure preparation of the wrong sequence still returns an excellent HPLC figure, which is why identity testing belongs on the qualification checklist rather than in the optional column.

Mass spectrometry is the workhorse here. The certificate should show observed mass alongside the theoretical mass calculated for the sequence, so a reviewer can see the comparison rather than take the conclusion. For a peptide of this length, a missing residue shifts mass enough to be detectable, but certain modifications do not: deamidation shifts mass by roughly one unit, and isomerization shifts it not at all. Distinguishing those requires higher-resolution work, MS/MS fragmentation, or peptide mapping.

A sensible approach scales the depth of testing to the decision being made. Deeper sequence confirmation — fragmentation data or amino acid analysis — makes most sense on the first lot you qualify from a new source, because that is the lot establishing whether the supplier's chemistry is what they say it is. Mass confirmation on every subsequent lot then tells you whether the source has stayed consistent. Buyers who reverse this order end up trusting a chain of identical-looking certificates that were never independently anchored.

Weight, water and counter-ions: what a 10 mg label measures

Lyophilized peptide is not dry peptide. The powder holds residual moisture, is hygroscopic once opened, and carries counter-ions — commonly acetate or trifluoroacetate — retained from cleavage and purification. Gross fill weight therefore overstates peptide mass, and by an amount that varies between lots unless it is actively controlled.

This is why net peptide content is a distinct question from purity, and why it is worth asking a supplier directly whether a labeled mass is gross or net. Two lots at the same stated purity can differ in actual peptide mass if only gross weight is specified. For any research program that depends on comparable material across repeat orders, consistency in water and counter-ion content is as important as the headline purity figure. Ask whether water content is determined by Karl Fischer or loss on drying, whether counter-ion content is assayed, and whether either is specified in the lot release criteria or merely measured and reported.

Auditing the documentation, not just the molecule

The supplier is part of what you are testing. Start with traceability: the lot number on the certificate must match the lot number on the vial, the test date must follow the manufacturing date, and the document must identify the laboratory that performed the work. A certificate with no lab name, no lot, or no date is a marketing artifact.

From there, ask procedural questions, because they predict what happens on your fifth order rather than your first. Is every batch tested, or was a single qualification lot tested and the results reused? Are retention samples kept so a disputed lot can be re-examined? Who holds the raw chromatographic data if a customer disputes an integration? Is testing performed in house, by an independent laboratory, or some mix — and is the mix disclosed per assay rather than implied by a generic third-party-tested badge?

Several practices common in this industry are worth treating as disqualifying rather than merely annoying. Pricing that only appears after a sales call makes comparison impossible and usually means tiers are negotiated rather than published. Certificates offered as a paid add-on convert basic evidence into an upsell. Testing described as verified with no laboratory named and no lot referenced cannot be checked by anyone. And documentation released only after a request form, on a case-by-case basis, means you cannot audit a supplier before you commit — which is precisely when auditing is useful. None of this requires naming competitors; it requires noticing which questions a supplier's process makes easy to answer.

Where compliance and scope questions belong

Whether your business may purchase, hold, repackage or resell research-use-only materials depends on your entity type, your professional licensing, your jurisdiction and the position of your state board — and those are questions for your own attorney and licensing authority, not for a supplier's blog. This article is informational and is not legal advice. Ask counsel what category your activity falls into, what records you are expected to keep, and what your obligations are when you transfer material to another party.

One boundary is not negotiable on the supply side: research compounds are not sold for human or animal use, and nothing here is guidance for administration. If your questions move toward application in a clinical setting, they belong with a licensed physician; if they concern animals, talk to your veterinarian. Analytical documentation answers whether material is what it claims to be — it never authorizes a use.

What Real Peptides does differently

Real Peptides builds its Wholesale Partner Program around documentation buyers can inspect before they commit rather than after. Catalog compounds are specified at 99%+ HPLC purity and every batch goes through 7-panel testing, with COAs published for verification — meaning a prospective partner can read the lab results themselves instead of filing a request and waiting for a sales representative to decide what to share. Orders ship from US fulfillment in 5–7 days, so restock planning does not depend on an overseas transit window. Onboarding is a 3-step wholesale application rather than an open-ended negotiation, and wholesale pricing is structured by tier instead of assembled per call. Buyers evaluating GHRH-axis material can review the lot documentation attached to a listing such as Tesamorelin 10mg and compare it against the checklist above before any conversation about volume takes place.

If you are a med spa, clinic, telehealth operator or reseller building a catalog and your current supplier cannot produce a lot-matched certificate with a readable chromatogram on request, the Wholesale Partner Program application is the next step — it takes three steps, and the documentation is available to review before you begin.

To see how the testing described here appears on live listings, the Tesamorelin 10mg page is a useful starting point, and buyers assessing the wider GH-axis category often compare it against CJC-1295 No DAC 10mg and Ipamorelin 10mg before reviewing the full Growth Factor & Tissue Signaling Research and Popular Peptides collections.